Breaking News


J&J's Janssen Must Pay $4 Million Over Topamax, Jury Says

Johnson & Johnson’s (JNJ) Janssen Pharmaceutical unit must pay $4.02 million in a lawsuit claiming that its seizure drug Topamax caused birth defects, a Philadelphia jury said.

Jurors in state court deliberated less than an hour before rendering a verdict in favor of Virginia resident April Czimmer who took the drug for six months and gave birth to a boy with cleft lip. Czimmer said her son Blake, born in September 2007, had injuries requiring four surgeries.

“This was our first case to go to trial and there are many more behind it,” Czimmer’s attorney Tommy Fibich said after the verdict. “This will expose the company to many more lawsuits.”

Czimmer’s case is the first of about 134 cases pending in state court in Philadelphia over the drug, plaintiffs’ lawyers said. Another trial began yesterday with opening statements on injuries suffered by a 5-year-old boy from South Carolina.

Topamax, approved by the U.S. Food and Drug Administration in 1996, was one of New Brunswick, New Jersey-based J&J’s top sellers before it lost patent protection in 2009. Czimmer took the drug from August 2006 through February 2007 to treat migraines.

The birth defects, known as oral clefts, range from a small notch in the lip to a groove that runs into the roof of the mouth and nose.

Johnson & Johnson rose 39 cents to $92.75 at 2:59 p.m. in New York. Before today, the shares had gained 35 percent this year.

The case is Czimmer v. Janssen Pharmaceuticals Inc., 110503459, Court of Common Pleas, Philadelphia County, Pennsylvania. The master case is In re Topamax Litigation, 110602131, Court of Common Pleas, Philadelphia County, Pennsylvania.

To contact the reporter on this story: Sophia Pearson in state court in Philadelphia at

To contact the editor responsible for this story: Michael Hytha at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.